Xilio Therapeutics Q4 EPS $0.81 Beats $(0.12) Estimate, Sales $13.686M Beat $7.960M Estimate

Xilio Therapeutics reported Q4 earnings of $0.81 per share, significantly surpassing the analyst estimate of $(0.12) by 775%. This represents a 128.93% improvement compared to losses of $(2.80) per share in the same quarter last year. The company also achieved quarterly sales of $13.686 million, exceeding the $7.960 million estimate by 71.93% and marking a 693.85% increase from $1.724 million in the prior year.